![BRF’s Entrepreneurial Accelerator Program portfolio company Embera NeuroTherapeutics announces first subject dosed in Phase 2 study of EMB-001 in cocaine use disorder](https://www.eapla.com/wp-content/uploads/2020/09/Screen-Shot-2020-09-01-at-1.53.36-PM-1080x675.png)
![BRF’s Entrepreneurial Accelerator Program portfolio company Embera NeuroTherapeutics announces first subject dosed in Phase 2 study of EMB-001 in cocaine use disorder](https://www.eapla.com/wp-content/uploads/2020/09/Screen-Shot-2020-09-01-at-1.53.36-PM-1080x675.png)
Recent Posts
Archives
- September 2022
- March 2022
- January 2022
- September 2021
- July 2021
- May 2021
- March 2021
- November 2020
- September 2020
- August 2020
- May 2020
- April 2020
- March 2020
- January 2020
- December 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- August 2018
- July 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017